Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Parsabiv™ (etelcalcetide) – New drug approval
February 7, 2017 – Amgen announced the FDA approval of Parsabiv (etelcalcetide), for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
